Advertisement

Topics

Search Results for "Sunitinib"

18:46 EDT 26th March 2017 | BioPortfolio

Matching Channels

None

Matching News

Kidney cancer: Intermittent sunitinib is an effective renal carcinoma treatment

Intermittent sunitinib treatment is a feasible first-line approach in patients with renal cell carcinoma (RCC), providing a median progression-free survival duration of 37.6 months. Cyclic re-introduc...

Early Intervention Important for Sunitinib-Related Hypertension in RCC

Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control.

Sunitinib Breaks Feasible for Treatment-Naive Metastatic RCC

Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy.

[News] Intermittent sunitinib for metastatic renal cell carcinoma

Intermittent treatment with sunitinib is feasible for patients with metastatic renal cell carcinoma and does not seem to compromise its activity, suggest findings from a phase 2 study.

Sunitinib Malate Market Forecast for Pancreatic Cancer, 20162017, G7 Countries, U.S., Germany, France, U.K., Italy, Spain, Japan Prices from USD $4650

The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 million by 2021, at a CAGR of 13.9% from 2016 to 2021. The growing incidence of pancreatic cancer especially pNET and i...

Renal-cell carcinoma in 2016: Advances in treatment — jostling for pole position

In 2016, two major trials provided conflicting evidence regarding the role of 1 year of adjuvant therapy with sunitinib for patients with high-risk renal-cell carcinoma. In the second-line metastatic ...

Roche combo doubles RCC survival vs sunitinib

Targeted therapy: Sunitinib modulates MCL-1 and mTOR signalling

Matching PubMed Articles

Sunitinib uptake inhibits platelet function in cancer patients.

Sunitinib is an oral tyrosine kinase inhibitor used for cancer treatment. Patients treated with sunitinib are at higher bleeding risk. As tyrosine kinases are essential for platelet signalling, the ef...

The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.

Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mec...

Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.

Coadministration of diclofenac and sunitinib, tyrosine kinase inhibitor, led to sex-divergent pharmacokinetic drug-drug interaction outcomes. Male and female mice were administered 60 mg/kg PO suniti...

Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.

Sunitinib is an orally delivered tyrosine kinase inhibitor that exhibits antiangiogenic effects. FDA has approved sunitinib for the treatment of metastatic renal cell carcinoma. However, its efficacy ...

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.

The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial an...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement